A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of CB03-154 as Adjunctive Therapy in Focal Epilepsy
Latest Information Update: 30 Sep 2024
At a glance
- Drugs CB 03 (Primary)
- Indications Partial epilepsies
- Focus Adverse reactions; Therapeutic Use
- Sponsors Shanghai Zhimeng Biopharma
- 30 Sep 2024 New trial record